Evidence map›Paper›PMID 39811550›Full record

ArticleERJ open research2025

Therapeutic doses of efzofitimod demonstrate efficacy in pulmonary sarcoidosis.

Ogugua Ndili Obi, Robert P Baughman, Elliott D Crouser, Mark W Julian, Landon W Locke, Abhijeeth Chandrasekaran, Pavithra Ramesh, Nelson Kinnersley, Vis Niranjan, Daniel A Culver and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. New Therapies for Sarcoidosis: Molecular and Pathophysiological Basis.International journal of molecular sciences · 2026
    Review
  3. Review
  4. Article
  5. WASOG Clinical Trial Endpoint Task Force: Executive Summary.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ogugua Ndili ObiDivision of Pulmonary, Critical Care, and Sleep Medicine, Brody School of Medicine, East Carolina University, Greenville, NC, USA.ORCID https://orcid.org/0000-0002-4692-1345
Robert P BaughmanDepartment of Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA.
Elliott D CrouserDivision of Pulmonary, Critical Care and Sleep Medicine, Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Mark W JulianDivision of Pulmonary, Critical Care and Sleep Medicine, Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Landon W LockeDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH, USA.
Abhijeeth ChandrasekaranRxMD, Chennai, India.
Pavithra RameshRxMD, Chennai, India.ORCID https://orcid.org/0000-0002-0227-5505
Nelson KinnersleyOcta Consulting Services Ltd, London, UK.ORCID https://orcid.org/0000-0002-7162-8677
Vis NiranjanRxMD, Chennai, India.ORCID https://orcid.org/0000-0002-2538-7980
Daniel A CulverDepartment of Pulmonary and Critical Care Medicine, Cleveland Clinic, Cleveland, OH, USA.
Peter H S SpornDivision of Pulmonary and Critical Care Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.ORCID https://orcid.org/0000-0002-1006-9437

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In a phase 1b/2a clinical trial of efzofitimod in patients with corticosteroid-requiring pulmonary sarcoidosis, treatment resulted in dose-dependent improvement in key end-points. We undertook a Methods: Peripheral blood mononuclear cells incubated with tuberculin-coated beads were exposed to varying concentrations of efzofitimod in an Results: Efzofitimod at ≥300 nM (19 µg·mL Conclusion: Treatment with efzofitimod at therapeutic doses, as compared with a subtherapeutic dose or placebo, was associated with a lower rate of relapse as corticosteroids were tapered.

Identifiers

PMID39811550
PMCPMC11726701

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.